Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2022 financial results.

“We are advancing our leading non-viral genetic medicine platform to unlock the potential of durable, redosable non-viral DNA therapeutics, and we have made significant progress in establishing the proprietary technologies necessary to realize our vision,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. “This quarter, process development and scaling of rapid enzymatic synthesis (RES) for production of our closed-ended DNA (ceDNA) construct has allowed us to pursue a more flexible and capital efficient manufacturing strategy. In the remainder of the year, we plan to continue to develop our unique cell-targeted lipid nanoparticle (ctLNP) system for systemic delivery to hepatocytes, as well as for other therapeutic areas such as the retina and vaccines.”

Business Highlights

• Announced update to Good Manufacturing Practice (GMP) manufacturing strategy: In June 2022, Generation Bio announced advances in process development for RES production of ceDNA that enabled a new modular and more flexible manufacturing approach. The productivity, high purity yield and short cycle time of RES at scale is expected to supply portfolio programs for the next 10 years and requires a much smaller manufacturing footprint than previously anticipated. The company is therefore seeking to assign its lease or sublease the manufacturing facility it had planned to build out and will execute an alternative GMP strategy that provides control over personnel, quality, infrastructure and process know-how while enhancing capital efficiency. As a result of the decision to assign or sublease the property, Generation Bio is able to reallocate financial resources from the buildout to extend its projected cash runway into 2025.
  
• Appointed Dannielle Appelhans to Board of Directors: In July 2022, the company announced the appointment of Dannielle Appelhans to its Board of Directors. Appelhans is an experienced pharmaceutical executive who has built deep expertise in strategy, manufacturing, supply chain and operations, and is currently the Chief Operating Officer of Rubius Therapeutics.
  

Second Quarter 2022 Financial Results

• Cash Position: Cash, cash equivalents and marketable securities were $312.2 million as of June 30, 2022, compared with $375.1 million in cash and cash equivalents as of December 31, 2021. The company believes that its cash position will fund its operating plan into 2025.
• R&D Expenses: Research and development (R&D) expenses were $28.4 million for the quarter ended June 30, 2022, compared to $22.7 million for the quarter ended June 30, 2021.
• G&A Expenses: General and administrative (G&A) expenses were $10.1 million for the quarter ended June 30, 2022, compared to $8.2 million for the quarter ended June 30, 2021.
• Net Loss: Net loss was $37.9 million, or $0.66 basic and diluted net loss per share, for the quarter ended June 30, 2022, compared to a net loss of $30.8 million, or $0.55 basic and diluted net loss per share, for the quarter ended June 30, 2021.

About Generation Bio
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

For more information, please visit www.generationbio.com. 

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the company, including statements about the company’s strategic plans or objectives, manufacturing plans, cash resources, technology platform, including RES, research and clinical development plans, and preclinical data and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials and clinical development of the company’s product candidates; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; whether results from earlier preclinical studies will be predictive of the results of later preclinical studies and clinical trials; uncertainties regarding the RES manufacturing process; uncertainties regarding the company’s ability to assign or sublease its manufacturing property; whether the changes to the company’s manufacturing strategy will achieve the anticipated savings; challenges in the manufacture of genetic medicine products; whether the company’s cash resources are sufficient to fund the company’s operating expenses and capital expenditure requirements for the period anticipated; the impact of the COVID-19 pandemic on the company’s business and operations; expectations for regulatory approvals to conduct trials or to market products; as well as the other risks and uncertainties set forth in the “Risk Factors” section of the company’s most recent annual report on Form 10-K and quarterly report on Form 10-Q, which are on file with the Securities and Exchange Commission, and in subsequent filings the company may make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof. The company anticipates that subsequent events and developments will cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date on which they were made.

Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638

GENERATION BIO CO.
CONSOLIDATED BALANCE SHEET DATA
(Unaudited)
(In thousands)

Earnings Release Balance Sheet	June 30, 2022				December 31, 2021
Cash, cash equivalents and marketable securities	$	312,204			$	375,145
Working capital		304,946				360,378
Total assets		418,994				476,771
Total stockholders’ equity		324,874				381,746

GENERATION BIO CO.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except share and per share data)

	Three Months Ended June 30,
		2022				2021
Operating expenses:
Research and development	$	28,365			$	22,656
General and administrative		10,116				8,186
Total operating expenses		38,481				30,842
Loss from operations		(38,481	)			(30,842	)
Other income:
Other income and interest income		552				51
Net loss and net loss attributable to common stockholders	$	(37,929	)		$	(30,791	)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.66	)		$	(0.55	)
Weighted average common shares outstanding, basic and diluted		57,149,474				56,318,025
Comprehensive loss:
Net loss	$	(37,929	)		$	(30,791	)
Other comprehensive loss:
Unrealized losses on marketable securities		(339	)			(6	)
Comprehensive loss	$	(38,268	)		$	(30,797	)